INDERIDE-40/25 Drug Patent Profile
✉ Email this page to a colleague
When do Inderide-40/25 patents expire, and what generic alternatives are available?
Inderide-40/25 is a drug marketed by Wyeth Pharms Inc and is included in one NDA.
The generic ingredient in INDERIDE-40/25 is hydrochlorothiazide; propranolol hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; propranolol hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INDERIDE-40/25?
- What are the global sales for INDERIDE-40/25?
- What is Average Wholesale Price for INDERIDE-40/25?
Summary for INDERIDE-40/25
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| DailyMed Link: | INDERIDE-40/25 at DailyMed |
US Patents and Regulatory Information for INDERIDE-40/25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms Inc | INDERIDE-40/25 | hydrochlorothiazide; propranolol hydrochloride | TABLET;ORAL | 018031-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
